The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.
from Front page feed https://ift.tt/2YJeYlo
from Front page feed https://ift.tt/2YJeYlo
Comments
Post a Comment